ABIVAX Société Anonyme (NASDAQ:ABVX) is ADAR1 Capital Management LLC’s 10th Largest Position

ADAR1 Capital Management LLC raised its position in ABIVAX Société Anonyme (NASDAQ:ABVX) by 190.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,513,393 shares of the company’s stock after buying an additional 991,781 shares during the quarter. ABIVAX Société Anonyme comprises about 2.2% of ADAR1 Capital Management LLC’s holdings, making the stock its 10th largest position. ADAR1 Capital Management LLC’s holdings in ABIVAX Société Anonyme were worth $11,078,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ABVX. Springhill Fund Asset Management HK Co Ltd purchased a new position in ABIVAX Société Anonyme during the fourth quarter worth about $1,520,000. Franklin Resources Inc. raised its position in ABIVAX Société Anonyme by 10.7% in the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock worth $10,732,000 after acquiring an additional 141,710 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $5,336,000. abrdn plc boosted its position in shares of ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company’s stock worth $3,105,000 after purchasing an additional 107,750 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth $36,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analyst Ratings Changes

ABVX has been the subject of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $38.00.

ABIVAX Société Anonyme Price Performance

Shares of ABVX opened at $5.32 on Monday. ABIVAX Société Anonyme has a 1 year low of $5.16 and a 1 year high of $16.63. The company’s 50 day simple moving average is $6.77 and its 200 day simple moving average is $8.12.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.